Publication date: Apr 15, 2025
Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in melanoma, dashing its hopes of moving the drug earlier in the treatment pathway. Opdualag which combines the PD-1 inhibitor nivolumab in BMS’ blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab was unable to improve on Opdivo alone in the RELATIVITY-098 study, which enrolled peopl .. .
| Concepts | Keywords |
|---|---|
| Cancer | Adjuvant |
| Drugmaker | Bms |
| Dwarfed | Cells |
| Company | |
| Drug | |
| Inhibitor | |
| Lag | |
| Line | |
| Melanoma | |
| Opdivo | |
| Opdualag | |
| Pd | |
| Relativity | |
| Relatlimab | |
| Study |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | melanoma |
| pathway | KEGG | Melanoma |
| drug | DRUGBANK | Nivolumab |
| disease | MESH | cancer |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | recurrence |
| disease | MESH | colorectal cancer |
| pathway | KEGG | Colorectal cancer |
| disease | MESH | non-small cell lung cancer |
| pathway | KEGG | Non-small cell lung cancer |
| disease | MESH | skin cancer |
| drug | DRUGBANK | Pembrolizumab |
| disease | MESH | head and neck cancer |
Original Article
(Visited 2 times, 1 visits today)